Cargando…

Lipoprotein(a) and PCSK9 inhibition: clinical evidence

Compelling evidence has emerged from epidemiological and Mendelian randomization analyses relative to the causality of lipoprotein(a) [Lp(a)] in atherosclerotic cardiovascular diseases (ASCVD), being elevated Lp(a) a strong risk factor regardless of the reduction of LDL-C achieved by statins. So far...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ruscica, Massimiliano, Greco, Maria Francesca, Ferri, Nicola, Corsini, Alberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673619/ https://www.ncbi.nlm.nih.gov/pubmed/33239979 http://dx.doi.org/10.1093/eurheartj/suaa135

Ejemplares similares

Hypocholesterolaemic treatment in coronary unit: from statins to anti PCSK9 therapies and bempedoic acid
por: Ferri, Nicola, et al.
Publicado: (2023)

PCSK9 Induces Rat Smooth Muscle Cell Proliferation and Counteracts the Pleiotropic Effects of Simvastatin
por: Lupo, Maria Giovanna, et al.
Publicado: (2021)

Impact of Soy β-Conglycinin Peptides on PCSK9 Protein Expression in HepG2 Cells
por: Macchi, Chiara, et al.
Publicado: (2021)

Naturally Occurring PCSK9 Inhibitors
por: Adorni, Maria Pia, et al.
Publicado: (2020)

PCSK9 Inhibition and Risk of Diabetes: Should We Worry?
por: Carugo, Stefano, et al.
Publicado: (2022)

Proprotein convertase subtilisin/kexin type 9: an update on the cardiovascular outcome studies
por: Ferri, Nicola, et al.
Publicado: (2020)

PCSK9 induces a pro-inflammatory response in macrophages
por: Ricci, Chiara, et al.
Publicado: (2018)

Lipoprotein(a) Lowering—From Lipoprotein Apheresis to Antisense Oligonucleotide Approach
por: Greco, Maria Francesca, et al.
Publicado: (2020)

PCSK9 Confers Inflammatory Properties to Extracellular Vesicles Released by Vascular Smooth Muscle Cells
por: Greco, Maria Francesca, et al.
Publicado: (2022)

Role of lipoprotein(a) in plaque progression
por: Ruscica, Massimiliano, et al.
Publicado: (2022)

PCSK9 Levels Are Raised in Chronic HCV Patients with Hepatocellular Carcinoma
por: Fasolato, Silvano, et al.
Publicado: (2020)

Associations Among PCSK9 Levels, Atherosclerosis-Derived Extracellular Vesicles, and Their miRNA Content in Adults With Obesity
por: Macchi, Chiara, et al.
Publicado: (2022)

The Role of High-Density Lipoprotein Cholesterol in 2022
por: Sirtori, Cesare R., et al.
Publicado: (2022)

PCSK9 Inhibition: Does Lipoprotein Size Matter?
por: Si‐Tayeb, Karim, et al.
Publicado: (2015)

Effect of a novel nutraceutical combination on serum lipoprotein functional profile and circulating PCSK9
por: Adorni, Maria Pia, et al.
Publicado: (2017)

Clinical approach to the inflammatory etiology of cardiovascular diseases
por: Ruscica, Massimiliano, et al.
Publicado: (2020)

Circulating PCSK9 as a prognostic biomarker of cardiovascular events in individuals with type 2 diabetes: evidence from a 16.8-year follow-up study
por: Ruscica, Massimiliano, et al.
Publicado: (2023)

PCSK9 and triglyceride-rich lipoprotein metabolism
por: Druce, Irena, et al.
Publicado: (2015)

Phage display for targeting PCSK9
por: Ferri, Nicola
Publicado: (2021)

Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans
por: Reyes-Soffer, Gissette, et al.
Publicado: (2017)

Proteomics and Lipidomics to unveil the contribution of PCSK9 beyond cholesterol lowering: a narrative review
por: Gianazza, Erica, et al.
Publicado: (2023)

New players in the treatment of hypercholesterolaemia: focus on bempedoic acid and inclisiran
por: Ruscica, Massimiliano, et al.
Publicado: (2021)

Fixed Combination for the Treatment of Dyslipidaemia
por: Ferri, Nicola, et al.
Publicado: (2023)

Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation
por: Kosenko, Tanja, et al.
Publicado: (2013)

Depression and cardiovascular risk—association among Beck Depression Inventory, PCSK9 levels and insulin resistance
por: Macchi, C., et al.
Publicado: (2020)

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
por: Schwartz, Gregory G., et al.
Publicado: (2021)

PCSK9 Expression in Epicardial Adipose Tissue: Molecular Association with Local Tissue Inflammation
por: Dozio, Elena, et al.
Publicado: (2020)

Relationship Between Low‐Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab
por: Shapiro, Michael D., et al.
Publicado: (2019)

High Density Lipoproteins Inhibit Oxidative Stress-Induced Prostate Cancer Cell Proliferation
por: Ruscica, Massimiliano, et al.
Publicado: (2018)

Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level
por: Afanasieva, Olga, et al.
Publicado: (2020)

PCSK9: The Nexus of Lipoprotein Metabolism and Inflammation in COVID-19
por: Goonewardena, Sascha N., et al.
Publicado: (2023)

Relationship between Circulating PCSK9 and Markers of Subclinical Atherosclerosis—The IMPROVE Study
por: Coggi, Daniela, et al.
Publicado: (2021)

Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia)
por: Waldmann, Elisa, et al.
Publicado: (2022)

Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor
por: Johns, Douglas G., et al.
Publicado: (2023)

Lipid Lowering Drugs: Present Status and Future Developments
por: Ruscica, Massimiliano, et al.
Publicado: (2021)

Proprotein Convertase Subtilisin/Kexin Type 9, Brain Cholesterol Homeostasis and Potential Implication for Alzheimer’s Disease
por: Adorni, Maria Pia, et al.
Publicado: (2019)

Impact of Atorvastatin on Skeletal Muscle Mitochondrial Activity, Locomotion and Axonal Excitability—Evidence from ApoE(-/-) Mice
por: Macchi, Chiara, et al.
Publicado: (2022)

Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol
por: Mohamed, Farzahna, et al.
Publicado: (2023)

Effect of PCSK9 Inhibition by Alirocumab on Lipoprotein Particle Concentrations Determined by Nuclear Magnetic Resonance Spectroscopy
por: Koren, Michael J., et al.
Publicado: (2015)

Effect of PCSK9 inhibitor on lipoprotein particles in patients with acute coronary syndromes
por: Li, Tingting, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9vd3hdih8r6dqrojs6m35lm64j